Satellos Bioscience Stock (NASDAQ:MSLE)

Ownership Financials Chart

Previous Close

$6.84

52W Range

$5.30 - $13.39

50D Avg

$8.94

200D Avg

$8.49

Market Cap

$8.32M

Avg Vol (3M)

$46.92K

Beta

1.17

Div Yield

-

MSLE Company Profile

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

18

IPO Date

Aug 03, 2012

Website

MSLE Performance

MSLE Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-26.46M	$-19.38M	$-11.66M
Net Income	$-24.87M	$-19.58M	$-11.98M
EBITDA	$-26.45M	$-19.56M	$-11.84M
Basic EPS	$-20.40	$-2.16	$-1.63
Diluted EPS	$-20.40	$-2.16	$-1.63

Fiscal year ends in Dec 25 | Currency in USD